Publications
View AllAtezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of his...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- DE
- Publications
- 5
- Citations
- 8,200
External Links
Identifiers
- ROR
- https://ror.org/02v4fpg03